Clinical trials: Advanced Malignancies, open to volunteers
Advanced Solid Tumor
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing…
- Trial name
- NCT05320874
- Testing
- KM257 Bispecific antibody
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with…
- Conditions
- Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy
- Trial name
- NCT05270824
- Testing
- radical surgery after neoadjuvant immunotherapy, radical surgery after neoadjuvant chemotherapy
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic…
- Trial name
- NCT05172518
- Testing
- Taxane plus Intermittent Capecitabine, Utidelone plus Intermittent Capecitabine, Taxane plus Metronomic Capecitabine
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Nasopharyngeal Carcinoma
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy combined with concurrent chemoradiotherapy in patients…
- Trial name
- NCT05062005
- Testing
- Induction Chemotherapy, Concurrent Chemotherapy, Definitive Radiotherapy
- Where
- China
- Volunteers
- 447 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Non-small Cell Lung Cancer
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
This is a phase II, multicenter, single-arm, non-blind study. To 21 patients with PD-L1 ≥50% locally advanced non-small cell lung cancer, the combination of Pembrolizumab and platinum-doublets will be intravenously administered…
- Trial name
- Evolution (NCT04153734)
- Testing
- Pembrolizumab, Cis Platinum, Carboplatin
- Volunteers
- 21 people
- Sponsor
- Kobe Minimally Invasive Cancer Center
Locally Advanced Gastric Cancer
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC).
- Trial name
- Neo-D2plus (NCT03961373)
- Testing
- Gastrectomy with D2 lymphadenectomy, Gastrectomy with D2plus lymphadenectomy
- Where
- Italy
- Volunteers
- 539 people
- Sponsor
- University of Siena
LOCALLY ADVANCED RECTAL CANCER
Organ Preservation in Locally Advanced Rectal Cancer
PRONAR trial aims to assess if treatment with organ preservation in stage II and III rectal cancer after a complete or almost complete response to neoadjuvant treatment is feasible and safe in our environment.
- Trial name
- PRONAR (NCT03064646)
- Testing
- Organ Preservation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Advanced Cancer
Molecular Tumor Board at the Center for Personalized Medicine Tübingen
Molecular Tumor Board at the Center for Personalized Medicine
- Trial name
- MTB@ZPM (NCT03503149)
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University Hospital Tuebingen
Locally Advanced Colon Cancer
Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy.
- Trial name
- NCT03125980
- Testing
- capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery
- Where
- China
- Volunteers
- 1,370 people
- Sponsor
- Fudan University